Asthma Research Today is a free monthly online journal that collates and summarizes the latest research about Asthma, including details on symptoms, diagnosis, treatment, causes, medications.

Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease.

Prenner BM

Division of Immunology and Allergy, UCSD College of Medicine Allergy Associates Medical Group, Inc., 6386 Alvarado Court Suite 210, San Diego, California 92120, USA. prenner@aaamg.com

Formoterol, a long-acting beta2-adrenergic agonist, is used as an inhaled bronchodilator therapy for patients with asthma or for the prevention of exercise-induced bronchospasm in children and in chronic obstructive pulmonary disease. Formoterol has unique characteristics of rapid onset and sustained duration of action compared with other bronchodilators. In addition to its effectiveness as regular maintenance therapy in asthma and chronic obstructive pulmonary disease, formoterol is also reported to be effective as an as-needed reliever therapy in patients with asthma. Formoterol is available in several different types of dry-powder inhalers and pressurized metered-dose inhalers.

Published 16 November 2007 in Expert Opin Pharmacother, 8(17): 3069-84.
Full-text of this article is available online (may require subscription).

© 2004-2008 Asthma Research Today. All Rights Reserved.